Botulinum toxin for aberrant facial nerve regeneration: Double-blind, placebo-controlled trial using subjective endpoints

Plastic and Reconstructive Surgery

Volumn 116, Issue 1, 2005, Pages 36-43

  Borodic, Gary ^a   Bartley, Mary ^b   Slattery, William ^b   Glasscock, Michael ^b   Johnson, Eric ^b   Malazio, Carl ^b   Goodnough, Michael ^b   Acquadro, Martin ^b   McKenna, Michael ^b  

^a Beyer Townsend and Borodic P C   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; EYELID MOVEMENT; FACIAL EXPRESSION; FACIAL NERVE; FACIAL NERVE PARALYSIS; FEMALE; HUMAN; MULTICENTER STUDY; NERVE REGENERATION; PALPEBRAL FISSURE; PERCEPTION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SOCIAL INTERACTION; VIDEORECORDING; VISION;

ADULT; BOTULINUM TOXIN TYPE A; CHRONIC DISEASE; DOUBLE-BLIND METHOD; FACIAL EXPRESSION; FACIAL MUSCLES; FACIAL NERVE; FACIAL PARALYSIS; FACTOR ANALYSIS, STATISTICAL; FEMALE; HUMANS; INTERPERSONAL RELATIONS; MALE; NERVE REGENERATION; NEUROMUSCULAR AGENTS; PILOT PROJECTS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 21744433138     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.PRS.0000169689.27829.C4     Document Type: Article

References (26)

1. House, J. W. Facial nerve grading scale. Laryngoscope 93: 1056, 1983.
2. Croxson, G., May, M., and Mester, S. J. Grading facial nerve function: House Brackmann versus Burres-Fisch methods. Am. J. Otol. 11: 240, 1990.
3. Boroojerdi, B., Ferbert, A., Schwarz, M., Herath, H., and Noth, J. Botulinum toxin treatment of synkinesia and hyperlacrimation in facial palsy. J. Neurol. Neurosurg. Psychiatry 65: 111, 1998.
4. Borodic, G. E., Pearce, L. B., Cheney, M., et al. Botulinum toxin for the treatment of aberrant facial nerve regeneration. Plast. Reconstr. Surg. 91: 1042, 1993.
5. Foda, H. M. Surgical management of lagophthalmos in patients with facial palsy. Plast. Reconstr. Surg. 20: 391, 1999.
6. Abell, K. M., Baker, R. S., Cowen, D. E., and Porter, J. D. Efficacy of gold weight implants in facial palsy: Quantitative alteration in blinking. Vision Res. 38: 3019, 1998.
7. Kinney, D. E., Seeley, B. M., Seeley, M. Z., and Foster, J. A. Oculoplastic surgical techniques for the protection of the eye in facial nerve paralysis. Am. J. Otol. 21: 275, 2000.
8. Megerian, C. A., McKenna, M. J., and Ojemann, R. G. Delayed facial nerve palsy after acoustic neuroma surgery: Factors influencing recovery. Am. J. Otol. 17: 630, 1996.
9. Johnson, E. A. Clostridial toxins as therapeutic agents: Benefits of nature's most toxic proteins. Annu. Rev. Microbiol. 53: 551, 1999.
10. Schantz, E. J., and Johnson, E. A. Botulinum toxin: The story of its development for the treatment of human disease. Perpect. Biol. Med. 40: 317, 1997.
11. Goodnough, M. C., and Johnson, E. A. Stabilization of botulinum toxin type A during lyophilization. Appl. Environ. Microbiol. 59: 2339, 1993.
12. Schantz, E. J., and Johnson, E. A. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol. Rev. 56: 80, 1992.
13. Borodic, G. E. Myasthenie crisis after botulinum toxin. Lancet 352: 832, 1998.
14. Frueh, B. R., Nelson, C. C., Kapustiak, J. F., and Musch, D. C. The effect of omitting botulinum toxin from the lower eyelid in blepharospasm treatment. Am. J. Ophthalmol. 106: 45, 1988.
15. Meyer, D. R., Linberg J. V., Powell, S. R., and Odom, J. V. Quantitating the superior visual field loss associated with ptosis. Arch. Ophthalmol. 107: 840, 1989.
16. Blumenfeld, A. Botulinum toxin type A as an effective prophylactic treatment in primary headache disorders. Headache 43: 853, 2003.
17. Dodick, D.W. Botulinum neurotoxin for the treatment of migraine and other primary headache disorders: From bench to bedside. Headache 43: S25, 2003.
18. Binder, W. J., Brin, M. F., Blitzer, A., Schoenrock, L. D., and Pogoda J. M. Botulinum toxin type A (BOTOX) for the treatment of migraine. Cephalgia 20: 422, 2000.
19. Smuts, J. A., and Barnard, P. W. Botulinum toxin type A in the treatment of headache syndromes: A clinical report of 79 patients. Cephalgia 20: 332, 2000.
20. Evers, S., Vollmer-Haase, J., Schwaag, S., Rahmann, A., Husstedt, I.-W., and Frese, A. Botulinum toxin A in the prophylactic treatment of migraine: A randomized double blind placebo controlled study. Cephalgia 24: 8838, 2004.
21. Carruthers, A, Carruthers, J., and Cohen, J. A prospective randomized double blind parallel dose ranging study of botulinum toxin type A in female subjects with horizontal forehead rhytides. Dermatol Surg. 29: 461, 2003.
22. Carruthers, J. A., Lowe, N. J., Menter, M. A., et al. A multicenter, double blind, randomized placebo controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J. Am. Acad. Dermatol. 46: 840, 2002.
23. Jensen, C., Devriese, P. P., Jennekens, F. G., and Wijnne, H. J. Lip-length and snout indices in Bell's palsy: A comparison with the House grading scale. Acta Otolarygol. 111: 1065, 1991.
24. Neely, J. G., Cheung, J. Y., Wood, M., Byers, J., and Rogerson, A. Computerized quantitative dynamic analysis of facial motion in paralyzed and synkinetic face. Am. J. Otol. 13: 97, 1992,
25. VanSwearingen, J. M., Cohn, J. F., Turnbull, J., Mrzai, T., and Johnson, P. Psychological distress: Linking impairment with disability in facial neuromotor disorders. Otolaryngol. Head Neck Surg. 18: 790, 1998.
26. Dulguerov, P., Quinodoz, D., Cosendai, G., Piletta, P., and Lehmann, W. Frey syndrome treatment with botulinum toxin. Otolaryngol. Head Neck Surg. 122: 821, 2000.